Alnylam Pharmaceuticals Inc (ALNY)vsGenmab AS (GMAB)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
GMAB
Genmab AS
$26.11
+1.16%
HEALTHCARE · Cap: $15.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Genmab AS generates 0% more annual revenue ($3.72B vs $3.71B). GMAB leads profitability with a 25.9% profit margin vs 8.5%. GMAB trades at a lower P/E of 16.8x. GMAB earns a higher WallStSmart Score of 54/100 (C-).
ALNY
Hold49
out of 100
Grade: D+
GMAB
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Margin of Safety
-187.1%
Fair Value
$10.47
Current Price
$26.11
$15.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 26 of every $100 in revenue as profit
Attractively priced relative to earnings
Strong operational efficiency at 23.0%
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Expensive relative to growth rate
3.0% revenue growth
Weak financial health signals
Earnings declined 94.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : GMAB
The strongest argument for GMAB centers on Price/Book, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 25.9% and operating margin at 23.0%.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : GMAB
The primary concerns for GMAB are PEG Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while GMAB is a value play — different risk/reward profiles.
GMAB carries more volatility with a beta of 0.75 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
GMAB generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
GMAB scores higher overall (54/100 vs 49/100), backed by strong 25.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Genmab AS
HEALTHCARE · BIOTECHNOLOGY · USA
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?